IPOGrid
0001620704
IPO filing research

MED-X, INC.

Agricultural Chemicals

ipo amended Nasdaq S-1

MED-X, INC. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-09-25. Current deal snapshot: exchange Nasdaq.

Filing Timeline

SEC EDGAR
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Common Stock · Exchange Nasdaq · Selling stockholders only · Use of proceeds Proceeds will be distributed to selling stockholders with no direct proceeds to the company
2026-09-25 · 0001477932-26-005809
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2026-06-11 · 0001477932-26-003813
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2026-05-12 · 0001477932-26-002999
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2026-04-17 · 0001477932-26-002370
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2026-03-27 · 0001477932-26-001630
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
2026-02-06 · 0001477932-26-000677
DRS filed
Draft registration statement
Draft registration filed confidentially before the public launch.
Begins the tracked draft filing sequence after RW.
2026-01-28 · 0001477932-26-000474
RW withdrawn
Withdrawal request
Issuer requested withdrawal of the registration statement.
Follows S-1/A and ends the active registration process.
2024-04-23 · 0001477932-24-002292
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · Range $4.00 to $6.00 · 1,150,000 shares
warrant to purchase one share · Exchange Nasdaq · Over-allotment 172,500 · Each Unit consists of one share of common stock and one warrant to purchase one share of common stock · Warrants to purchase 1,150,000 shares of common stock exercisable at 100% of the initial public offering price for five years · Use of proceeds To fund the acquisition of Napco Painting Contractors, Inc. and for general corporate purposes · Flags units, warrants · Underwriters Maxim Group LLC
2024-02-09 · 0001477932-24-000633
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · Range $4.00 to $6.00 · 1,150,000 shares · Gross proceeds $5,750,000
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 172,500 · Warrants to purchase up to 5% of shares sold in offering (3% for shares introduced by Company) · Use of proceeds To fund the acquisition of Napco Painting Contractors, Inc. · Flags warrants · Underwriters Maxim Group LLC
2023-10-27 · 0001477932-23-007926
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · Range $4.00 to $6.00 · 1,150,000 shares · Gross proceeds $5,750,000
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 172,500 · Warrants to purchase up to 5% of shares sold · Use of proceeds debt repayment, working capital, acquisitions · Flags warrants · Underwriters Maxim Group LLC
2023-10-03 · 0001477932-23-007319
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $4.00 · 2,125,000 shares · Gross proceeds $8,500,000
Common Stock, par value $0.001 per share · Exchange Nasdaq · Ticker MXRX · Over-allotment 318,750 · Use of proceeds debt repayment, working capital, acquisitions · Underwriters R.F. Lafferty & Co., Inc.
2023-06-07 · 0001477932-23-004277
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $4.00 · 2,125,000 shares · Gross proceeds $8,500,000
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 318,750 · Use of proceeds for working capital and general corporate purposes · Underwriters R.F. Lafferty & Co., Inc.
2023-05-15 · 0001477932-23-003546
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $4.00 · 2,125,000 shares · Gross proceeds $8,500,000
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 318,750 · Use of proceeds Proceeds to Med-X, Inc. · Underwriters EF Hutton, division of Benchmark Investments, LLC, CRAFT CAPITAL MANAGEMENT, LLC
2022-10-26 · 0001477932-22-007917
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $4.15 · Range $4.00 to $4.30 · 1,686,747 shares
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 253,012 · Use of proceeds working capital · Underwriters EF Hutton, division of Benchmark Investments, LLC
2022-09-23 · 0001477932-22-007157
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
Price $4.15 · Range $4.00 to $4.30 · 1,686,747 shares
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 262,500 · Underwriters EF Hutton, division of Benchmark Investments, LLC
2022-09-19 · 0001477932-22-007030
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
2022-09-08 · 0001477932-22-006725
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2022-08-04 · 0001477932-22-005646
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2022-07-21 · 0001477932-22-005277
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2022-06-21 · 0001477932-22-004538
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
MED-X, Inc. filed a DRS/A on 2022-05-06, disclosing financial restatements for 2020, adjustments to inventory, cost of goods sold, and operating expenses. The company operates in three product segments (Nature-Cide, Thermal-Aid, Malibu Brands) with revenue primarily from e-commerce and distributors. Key financial highlights include a $1.01M total revenue in 2021, $332,971 in rent expenses, and a $1.15M lease liability. The filing also details related party transactions, supplier concentration risks, and a $736 annual imputed rent from an executive.
2022-05-06 · 0001477932-22-003014
DRS filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
MED-X, Inc. is conducting an IPO with a proposed 1-for-8 reverse stock split, aiming to list on Nasdaq under the symbol 'MXRX'. The offering is underwritten by EF Hutton, division of Benchmark Investments, LLC, with lock-up agreements for officers and directors. The company outlines indemnification policies for directors/officers and details restrictions on future share sales, including Rule 144 and Rule 701 compliance. A warrant component is included for the underwriters, with specific registration rights and anti-dilution provisions.
2022-02-10 · 0001477932-22-000653
Comparable Deals

20 comparable deals

Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 20 using nearest neighbors.
Showing top 8 by similarity.
+12.0%
Median day-1
60%
Above issue
+14.2%
Median week-1
-11.7%
Downside (p10)
ADARx Pharmaceuticals, Inc. ADRX
2026-09-25 $446M Day 1: +13.8% Wk 1: +17.0%
same SIC grouprecent IPO
Electra Therapeutics, Inc. ETRA
2026-09-18 $350M Day 1: -11.7% Wk 1: -21.2%
same SIC grouprecent IPO
Vogenx, Inc. VOGX
2026-08-12 $81M Day 1: +0.0% Wk 1: +51.9%
same SIC grouprecent IPO
BlossomHill Therapeutics, Inc. BLSM
2026-08-07 $150M Day 1: +0.0% Wk 1: +2.2%
same SIC grouprecent IPO
Latigo Biotherapeutics, Inc. LTGO
2026-08-07 $346M Day 1: +1.4% Wk 1: +11.4%
same SIC grouprecent IPO
Braveheart Bio, Inc. BRVE
2026-08-06 $383M Day 1: +65.6% Wk 1: +45.3%
same SIC grouprecent IPO
Attovia Therapeutics, Inc. ATTO
2026-08-05 $269M Day 1: +28.8% Wk 1: +9.7%
same SIC grouprecent IPO
Apnimed, Inc. APMD
2026-07-31 $192M Day 1: +43.6% Wk 1: +74.3%
same SIC grouprecent IPO

Recent News

No recent news stored for this issuer.